Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said.

Illustration: Elizabeth Smelov Novo Nordisk shares dived Friday after an experimental anti-obesity treatment missed ...

A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

Over the past few months, Blue Cross Blue Shield of Michigan, the state’s largest insurer, has scaled back on coverage of the ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 471.82% and ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

Skipping certain foods can help patients manage nausea and other side effects of the popular drugs, doctors say.